赖氨匹林和布洛芬钠预防早产儿动脉导管未闭。

Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.

机构信息

Division of Neonatology, Department of Paediatrics, Catholic University of Sacred Heart, Rome, Italy.

出版信息

Indian Pediatr. 2012 Jan;49(1):47-9. doi: 10.1007/s13312-012-0006-8. Epub 2011 Aug 15.

PMID:21992864

Abstract

This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤ 28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1% vs 50%; P=0.002) and surgical ligation significantly lower (8.2% vs 23.3%; P=0.005) in Group I. A smaller number of neonates of Group I vs Group II showed oliguria and hemorrhagic disease.

摘要

这项回顾性研究比较了在 2000-2005 年期间使用的赖氨酸布洛芬（肌肉注射制剂，I 组，n=156）和在 2006-2008 年期间使用的布洛芬钠（静脉注射溶液，II 组，n=60）用于预防胎龄≤28 周的先天性新生儿动脉导管未闭的疗效和安全性。预防后动脉导管关闭率显著更高（73.1% vs 50%；P=0.002），手术结扎率显著更低（8.2% vs 23.3%；P=0.005）。I 组中出现少尿和出血性疾病的新生儿数量也较少。